{"database": "lobbying", "table": "lobbying_activities", "rows": [[2394764, "d5b9b497-6b09-4d93-908a-19ce9ae7653f", "Q4", "EMERGENT BIOSOLUTIONS INC.", 304931, "EMERGENT BIOSOLUTIONS INC", 2019, "fourth_quarter", "DIS", "-FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government\n-NDAA - provisions related to biological and chemical defense\n-Department of Defense appropriations for Medical Countermeasures\n-FDA regulatory issues\n-Issues related to Priority Review Voucher programs\n-Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines", "HOUSE OF REPRESENTATIVES,SENATE", null, 730000, 0, 0, "2020-01-20T11:38:59.337000-05:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2394764"], "units": {}, "query_ms": 0.3690350567921996, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}